

# SAFETY DATA SHEET



## Betamethasone / Clotrimazole Ointment Formulation



Version 8.0      Revision Date: 06.04.2024      SDS Number: 610359-00020      Date of last issue: 30.09.2023  
Date of first issue: 08.04.2016

---

### SECTION 1: Identification of the substance/mixture and of the company/undertaking

#### 1.1 Product identifier

Trade name : Betamethasone / Clotrimazole Ointment Formulation

#### 1.2 Relevant identified uses of the substance or mixture and uses advised against

Use of the Substance/Mixture : Pharmaceutical

Recommended restrictions on use : Not applicable

#### 1.3 Details of the supplier of the safety data sheet

Company : Organon & Co.  
30 Hudson Street, 33rd floor  
07302 Jersey City, New Jersey, U.S.A

Telephone : +1-551-430-6000

E-mail address of person responsible for the SDS : EHSSTEWARD@organon.com

#### 1.4 Emergency telephone number

+1-215-631-6999

---

### SECTION 2: Hazards identification

#### 2.1 Classification of the substance or mixture

##### Classification (REGULATION (EC) No 1272/2008)

Reproductive toxicity, Category 1B

Specific target organ toxicity - repeated exposure, Category 1

Long-term (chronic) aquatic hazard, Category 1

H360D: May damage the unborn child.

H372: Causes damage to organs through prolonged or repeated exposure.

H410: Very toxic to aquatic life with long lasting effects.

#### 2.2 Label elements

##### Labelling (REGULATION (EC) No 1272/2008)

Hazard pictograms :



Signal word : Danger

Hazard statements : H360D May damage the unborn child.  
H372 Causes damage to organs through prolonged or re-

---

# SAFETY DATA SHEET



## Betamethasone / Clotrimazole Ointment Formulation



Version 8.0      Revision Date: 06.04.2024      SDS Number: 610359-00020      Date of last issue: 30.09.2023  
Date of first issue: 08.04.2016

peated exposure.  
H410 Very toxic to aquatic life with long lasting effects.

Precautionary statements :

### Prevention:

P201 Obtain special instructions before use.  
P264 Wash skin thoroughly after handling.  
P273 Avoid release to the environment.  
P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.

### Response:

P308 + P313 IF exposed or concerned: Get medical advice/ attention.  
P391 Collect spillage.

Hazardous components which must be listed on the label:

betamethasone

### 2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

## SECTION 3: Composition/information on ingredients

### 3.2 Mixtures

#### Components

Chemical name	CAS-No. EC-No. Index-No. Registration number	Classification	Concentration (% w/w)
clotrimazole	23593-75-1 245-764-8	Acute Tox. 4; H302 Acute Tox. 3; H311 Eye Irrit. 2; H319 Repr. 2; H361fd STOT RE 2; H373 (Liver, Kidney, Adrenal gland) Aquatic Acute 1; H400 Aquatic Chronic 1; H410  M-Factor (Acute aquatic toxicity): 10 M-Factor (Chronic aquatic toxicity): 10	>= 1 - < 2,5
betamethasone	378-44-9 206-825-4	Acute Tox. 2; H330 Repr. 1B; H360D STOT RE 1; H372 (Pituitary gland,	>= 0,025 - < 0,1

# Betamethasone / Clotrimazole Ointment For- mulation

Version 8.0	Revision Date: 06.04.2024	SDS Number: 610359-00020	Date of last issue: 30.09.2023 Date of first issue: 08.04.2016
----------------	------------------------------	-----------------------------	---

			Immune system, muscle, thymus gland, Blood, Ad- renal gland) Aquatic Chronic 1; H410 <hr/> M-Factor (Chronic aquatic toxicity): 1.000
--	--	--	---

For explanation of abbreviations see section 16.

## SECTION 4: First aid measures

### 4.1 Description of first aid measures

- General advice : In the case of accident or if you feel unwell, seek medical advice immediately.  
When symptoms persist or in all cases of doubt seek medical advice.
- Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
- If inhaled : If inhaled, remove to fresh air.  
Get medical attention.
- In case of skin contact : In case of contact, immediately flush skin with soap and plenty of water.  
Remove contaminated clothing and shoes.  
Get medical attention.  
Wash clothing before reuse.  
Thoroughly clean shoes before reuse.
- In case of eye contact : Flush eyes with water as a precaution.  
Get medical attention if irritation develops and persists.
- If swallowed : If swallowed, DO NOT induce vomiting.  
Get medical attention.  
Rinse mouth thoroughly with water.

### 4.2 Most important symptoms and effects, both acute and delayed

- Risks : May damage the unborn child.  
Causes damage to organs through prolonged or repeated exposure.

### 4.3 Indication of any immediate medical attention and special treatment needed

- Treatment : Treat symptomatically and supportively.

## Betamethasone / Clotrimazole Ointment Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
8.0	06.04.2024	610359-00020	Date of first issue: 08.04.2016

---

---

### SECTION 5: Firefighting measures

#### 5.1 Extinguishing media

Suitable extinguishing media : Water spray  
Alcohol-resistant foam  
Carbon dioxide (CO<sub>2</sub>)  
Dry chemical

Unsuitable extinguishing media : None known.

#### 5.2 Special hazards arising from the substance or mixture

Specific hazards during fire-fighting : Exposure to combustion products may be a hazard to health.

Hazardous combustion products : Carbon oxides

#### 5.3 Advice for firefighters

Special protective equipment for firefighters : In the event of fire, wear self-contained breathing apparatus.  
Use personal protective equipment.

Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.  
Use water spray to cool unopened containers.  
Remove undamaged containers from fire area if it is safe to do so.  
Evacuate area.

---

### SECTION 6: Accidental release measures

#### 6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions : Use personal protective equipment.  
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

#### 6.2 Environmental precautions

Environmental precautions : Avoid release to the environment.  
Prevent further leakage or spillage if safe to do so.  
Retain and dispose of contaminated wash water.  
Local authorities should be advised if significant spillages cannot be contained.

#### 6.3 Methods and material for containment and cleaning up

Methods for cleaning up : Sweep up or vacuum up spillage and collect in suitable container for disposal.  
Local or national regulations may apply to releases and dis-

# Betamethasone / Clotrimazole Ointment For- mulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
8.0	06.04.2024	610359-00020	Date of first issue: 08.04.2016

---

posal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

## 6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

---

## SECTION 7: Handling and storage

### 7.1 Precautions for safe handling

- |                         |   |  |
|-------------------------|---|--|
| Technical measures      | : | See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.  |
| Local/Total ventilation | : | If sufficient ventilation is unavailable, use with local exhaust ventilation.  |
| Advice on safe handling | : | Do not get on skin or clothing.<br>Do not breathe dust, fume, gas, mist, vapours or spray.<br>Do not swallow.<br>Avoid contact with eyes.<br>Wash skin thoroughly after handling.<br>Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment<br>Keep container tightly closed.<br>Do not eat, drink or smoke when using this product.<br>Take care to prevent spills, waste and minimize release to the environment.      |
| Hygiene measures        | : | If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use.<br>The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls. |

### 7.2 Conditions for safe storage, including any incompatibilities

- |   |   |  |
|---|---|--|
| Requirements for storage areas and containers | : | Keep in properly labelled containers. Store locked up. Keep tightly closed. Store in accordance with the particular national regulations.                      |
| Advice on common storage                      | : | Do not store with the following product types:<br>Strong oxidizing agents<br>Self-reactive substances and mixtures<br>Organic peroxides<br>Explosives<br>Gases |

### 7.3 Specific end use(s)

- |                 |   |                   |
|-----------------|---|-------------------|
| Specific use(s) | : | No data available |
|-----------------|---|-------------------|

# Betamethasone / Clotrimazole Ointment Formulation

Version 8.0      Revision Date: 06.04.2024      SDS Number: 610359-00020      Date of last issue: 30.09.2023  
Date of first issue: 08.04.2016

## SECTION 8: Exposure controls/personal protection

### 8.1 Control parameters

#### Occupational Exposure Limits

Components	CAS-No.	Value type (Form of exposure)	Control parameters	Basis
clotrimazole	23593-75-1	TWA	0.2 mg/m <sup>3</sup> (OEB 2)	Internal
betamethasone	378-44-9	TWA	1 µg/m <sup>3</sup> (OEB 4)	Internal
Further information: Skin				
		Wipe limit	10 µg/100 cm <sup>2</sup>	Internal

#### Predicted No Effect Concentration (PNEC) according to Regulation (EC) No. 1907/2006:

Substance name	Environmental Compartment	Value
Petrolatum	Oral (Secondary Poisoning)	9,33 mg/kg food

### 8.2 Exposure controls

#### Engineering measures

Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., vacuum conveying from a closed system, packout head with inflatable seal from stationary container, ventilated enclosure, etc.).

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Essentially no open handling permitted.

Use closed processing systems or containment technologies.

#### Personal protective equipment

- Eye/face protection : Wear safety glasses with side shields or goggles.  
If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.  
Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.
- Hand protection
- Material : Chemical-resistant gloves
- Remarks : Consider double gloving.
- Skin and body protection : Work uniform or laboratory coat.  
Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces.  
Use appropriate degowning techniques to remove potentially contaminated clothing.
- Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.
- Filter type : Combined particulates and organic vapour type (A-P)

**Betamethasone / Clotrimazole Ointment Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
8.0	06.04.2024	610359-00020	Date of first issue: 08.04.2016

---

**SECTION 9: Physical and chemical properties****9.1 Information on basic physical and chemical properties**

Appearance	:	Viscous semi-solid
Colour	:	No data available
Odour	:	No data available
Odour Threshold	:	No data available
pH	:	No data available
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flash point	:	Not applicable
Evaporation rate	:	Not applicable
Flammability (solid, gas)	:	Not classified as a flammability hazard
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Vapour pressure	:	Not applicable
Relative vapour density	:	Not applicable
Relative density	:	No data available
Density	:	No data available
Solubility(ies)		
Water solubility	:	No data available
Partition coefficient: n-octanol/water	:	Not applicable
Auto-ignition temperature	:	No data available
Decomposition temperature	:	No data available
Viscosity		
Viscosity, kinematic	:	No data available
Explosive properties	:	Not explosive
Oxidizing properties	:	The substance or mixture is not classified as oxidizing.

**9.2 Other information**

Flammability (liquids)	:	No data available
------------------------	---	-------------------

**Betamethasone / Clotrimazole Ointment For-  
mulation**

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
8.0	06.04.2024	610359-00020	Date of first issue: 08.04.2016

---

Particle size : Not applicable

---

**SECTION 10: Stability and reactivity****10.1 Reactivity**

Not classified as a reactivity hazard.

**10.2 Chemical stability**

Stable under normal conditions.

**10.3 Possibility of hazardous reactions**

Hazardous reactions : Can react with strong oxidizing agents.

**10.4 Conditions to avoid**

Conditions to avoid : None known.

**10.5 Incompatible materials**

Materials to avoid : Oxidizing agents

**10.6 Hazardous decomposition products**

No hazardous decomposition products are known.

---

**SECTION 11: Toxicological information****11.1 Information on toxicological effects**

Information on likely routes of exposure : Skin contact  
Ingestion  
Eye contact

**Acute toxicity**

Not classified based on available information.

**Product:**

Acute oral toxicity : Acute toxicity estimate: > 2.000 mg/kg  
Method: Calculation method

Acute dermal toxicity : Acute toxicity estimate: > 2.000 mg/kg  
Method: Calculation method

**Components:****clotrimazole:**

Acute oral toxicity : LD50 (Rat): 708 mg/kg  
LD50 (Mouse): 761 mg/kg  
LD50 (Rabbit): > 1.000 mg/kg

---



**Betamethasone / Clotrimazole Ointment For-  
mulation**

Version 8.0      Revision Date: 06.04.2024      SDS Number: 610359-00020      Date of last issue: 30.09.2023  
Date of first issue: 08.04.2016

---

Acute inhalation toxicity : LC50 (Rat): > 0,73 mg/l  
Exposure time: 4 h  
Test atmosphere: dust/mist

Acute dermal toxicity : LD50 (Mouse): 923 mg/kg

**betamethasone:**

Acute oral toxicity : LD50 (Rat): > 5.000 mg/kg  
LD50 (Mouse): > 4.500 mg/kg

Acute inhalation toxicity : LC50 (Rat): 0,4 mg/l  
Exposure time: 4 h

**Skin corrosion/irritation**

Not classified based on available information.

**Components:****clotrimazole:**

Species : Rabbit  
Result : No skin irritation

**betamethasone:**

Species : Rabbit  
Result : Mild skin irritation

**Serious eye damage/eye irritation**

Not classified based on available information.

**Components:****clotrimazole:**

Species : Rabbit  
Result : Mild eye irritation

**betamethasone:**

Species : Rabbit  
Result : No eye irritation

**Respiratory or skin sensitisation****Skin sensitisation**

Not classified based on available information.

**Respiratory sensitisation**

Not classified based on available information.

**Components:****betamethasone:**

# Betamethasone / Clotrimazole Ointment For- mulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
8.0	06.04.2024	610359-00020	Date of first issue: 08.04.2016

Exposure routes	:	Dermal
Species	:	Guinea pig
Result	:	Weak sensitizer

### Germ cell mutagenicity

Not classified based on available information.

### Components:

#### **clotrimazole:**

Genotoxicity in vitro	:	Test Type: Bacterial reverse mutation assay (AMES) Result: negative
		Test Type: Chromosome aberration test in vitro Result: negative
		Test Type: in vitro micronucleus test Result: negative
Genotoxicity in vivo	:	Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay) Species: Rat Application Route: Oral Result: negative
		Test Type: Mammalian spermatogonial chromosome aberration test (in vivo) Species: Hamster Result: negative
Germ cell mutagenicity- Assessment	:	Weight of evidence does not support classification as a germ cell mutagen.

#### **betamethasone:**

Genotoxicity in vitro	:	Test Type: Bacterial reverse mutation assay (AMES) Result: negative
		Test Type: In vitro mammalian cell gene mutation test Result: negative
		Test Type: Chromosome aberration test in vitro Result: positive
Genotoxicity in vivo	:	Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay) Species: Mouse Application Route: Oral Result: equivocal
Germ cell mutagenicity- Assessment	:	Weight of evidence does not support classification as a germ cell mutagen.

# Betamethasone / Clotrimazole Ointment Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
8.0	06.04.2024	610359-00020	Date of first issue: 08.04.2016

## Carcinogenicity

Not classified based on available information.

## Components:

### clotrimazole:

Species	:	Rat
Application Route	:	Oral
Exposure time	:	78 weeks
Result	:	negative

## Reproductive toxicity

May damage the unborn child.

## Components:

### clotrimazole:

Effects on fertility	:	Test Type: Fertility/early embryonic development Species: Rat Application Route: Oral Fertility: LOAEL: 50 mg/kg body weight Result: Effects on fertility
Effects on foetal development	:	Test Type: Embryo-foetal development Species: Rat Application Route: Oral Developmental Toxicity: LOAEL: 100 mg/kg body weight Result: Embryo-foetal toxicity, No teratogenic effects
		Test Type: Embryo-foetal development Species: Rat Application Route: Oral Developmental Toxicity: NOAEL: 50 mg/kg body weight Result: Embryo-foetal toxicity, No teratogenic effects
		Test Type: Embryo-foetal development Species: Mouse Application Route: Oral Developmental Toxicity: NOAEL: 200 mg/kg body weight Result: No effects on foetal development
		Test Type: Embryo-foetal development Species: Rabbit Application Route: Oral Developmental Toxicity: NOAEL: 180 mg/kg body weight Result: No effects on foetal development
Reproductive toxicity - Assessment	:	Some evidence of adverse effects on sexual function and fertility, based on animal experiments., Some evidence of adverse effects on development, based on animal experiments.

### betamethasone:

# Betamethasone / Clotrimazole Ointment Formulation

Version 8.0      Revision Date: 06.04.2024      SDS Number: 610359-00020      Date of last issue: 30.09.2023  
Date of first issue: 08.04.2016

Effects on foetal development : Species: Rabbit  
Application Route: Intramuscular  
Developmental Toxicity: LOAEL: 0,05 mg/kg body weight  
Result: Fetotoxicity, Malformations were observed.

Species: Rat  
Application Route: Subcutaneous  
Developmental Toxicity: LOAEL: 0,42 mg/kg body weight  
Result: Malformations were observed.

Species: Mouse  
Application Route: Intramuscular  
Developmental Toxicity: LOAEL: 1 mg/kg body weight  
Result: Malformations were observed.

Reproductive toxicity - Assessment : Clear evidence of adverse effects on development, based on animal experiments.

### STOT - single exposure

Not classified based on available information.

### STOT - repeated exposure

Causes damage to organs through prolonged or repeated exposure.

### Components:

#### clotrimazole:

Target Organs : Liver, Kidney, Adrenal gland  
Assessment : May cause damage to organs through prolonged or repeated exposure.

#### betamethasone:

Target Organs : Pituitary gland, Immune system, muscle, thymus gland, Blood, Adrenal gland  
Assessment : Causes damage to organs through prolonged or repeated exposure.

### Repeated dose toxicity

### Components:

#### clotrimazole:

Species : Rabbit  
LOAEL : 5 - 40 mg/kg  
Application Route : Skin contact  
Exposure time : 3 Weeks  
Target Organs : Skin  
Symptoms : Oedema, Fissuring, Necrosis, Redness

Species : Rat  
LOAEL : 10 mg/kg  
Application Route : Oral  
Exposure time : 18 Months

# Betamethasone / Clotrimazole Ointment Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
8.0	06.04.2024	610359-00020	Date of first issue: 08.04.2016

---

|| Target Organs : Liver, Kidney, Adrenal gland

|| Species : Dog  
 || LOAEL : 25 mg/kg  
 || Application Route : Oral  
 || Exposure time : 6 - 12 Months  
 || Target Organs : Adrenal gland  
 || Symptoms : Salivation, Lachrymation, Vomiting

### betamethasone:

|| Species : Rabbit  
 || LOAEL : 0.05 %  
 || Application Route : Skin contact  
 || Exposure time : 10 - 30 d  
 || Target Organs : Pituitary gland, Immune system, muscle

|| Species : Rat  
 || LOAEL : 0.05 %  
 || Application Route : Skin contact  
 || Exposure time : 8 Weeks  
 || Target Organs : thymus gland

|| Species : Mouse  
 || LOAEL : 0.1 %  
 || Application Route : Skin contact  
 || Exposure time : 8 Weeks  
 || Target Organs : thymus gland

|| Species : Dog  
 || LOAEL : 0,05 mg/kg  
 || Application Route : Oral  
 || Exposure time : 28 d  
 || Target Organs : Blood, thymus gland, Adrenal gland

### Aspiration toxicity

Not classified based on available information.

### Experience with human exposure

#### Components:

#### clotrimazole:

|| Skin contact : Symptoms: Rash, Itching, Blistering, Oedema, Redness  
 || Ingestion : Symptoms: Abdominal pain, Nausea, Vomiting, Diarrhoea

#### betamethasone:

|| Inhalation : Target Organs: Adrenal gland  
 || Skin contact : Symptoms: Redness, pruritis, Irritation

# Betamethasone / Clotrimazole Ointment Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
8.0	06.04.2024	610359-00020	Date of first issue: 08.04.2016

## SECTION 12: Ecological information

### 12.1 Toxicity

#### Components:

##### **clotrimazole:**

Toxicity to fish	:	LC50 (Brachydanio rerio (zebrafish)): > 0,29 mg/l Exposure time: 96 h Method: OECD Test Guideline 203
Toxicity to daphnia and other aquatic invertebrates	:	EC50 (Daphnia magna (Water flea)): 0,02 mg/l Exposure time: 48 h
Toxicity to algae/aquatic plants	:	EC50 (Desmodesmus subspicatus (green algae)): 0,268 mg/l Exposure time: 72 h  NOEC (Desmodesmus subspicatus (green algae)): 0,017 mg/l Exposure time: 72 h
M-Factor (Acute aquatic toxicity)	:	10
Toxicity to microorganisms	:	EC50 : > 10.000 mg/l Exposure time: 3 h Test Type: Respiration inhibition Method: OECD Test Guideline 209
Toxicity to fish (Chronic toxicity)	:	NOEC: 0,025 mg/l Exposure time: 32 d Species: Oncorhynchus mykiss (rainbow trout) Method: OECD Test Guideline 210
Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity)	:	NOEC: 0,01 mg/l Exposure time: 21 d Species: Daphnia magna (Water flea) Method: OECD Test Guideline 211
M-Factor (Chronic aquatic toxicity)	:	10

##### **betamethasone:**

Toxicity to daphnia and other aquatic invertebrates	:	EC50 (Americamysis): > 50 mg/l Exposure time: 96 h
Toxicity to algae/aquatic plants	:	EC50 (Pseudokirchneriella subcapitata (green algae)): > 34 mg/l Exposure time: 72 h Method: OECD Test Guideline 201 Remarks: No toxicity at the limit of solubility  NOEC (Pseudokirchneriella subcapitata (green algae)): 34 mg/l

# Betamethasone / Clotrimazole Ointment Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
8.0	06.04.2024	610359-00020	Date of first issue: 08.04.2016

	Exposure time: 72 h Method: OECD Test Guideline 201 Remarks: No toxicity at the limit of solubility
Toxicity to fish (Chronic toxicity)	: NOEC: 0,052 mg/l Exposure time: 32 d Species: Pimephales promelas (fathead minnow) Method: OECD Test Guideline 210
	NOEC: 0,07 µg/l Exposure time: 219 d Species: Oryzias latipes (Japanese medaka) Method: OECD Test Guideline 229
Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity)	: NOEC: 8 mg/l Exposure time: 21 d Species: Daphnia magna (Water flea) Method: OECD Test Guideline 211
M-Factor (Chronic aquatic toxicity)	: 1.000

## 12.2 Persistence and degradability

### Components:

#### **clotrimazole:**

Stability in water	: Hydrolysis: 50 %(242 d)
--------------------	---------------------------

## 12.3 Bioaccumulative potential

### Components:

#### **betamethasone:**

Partition coefficient: n-octanol/water	: log Pow: 2,11
--	-----------------

## 12.4 Mobility in soil

No data available

## 12.5 Results of PBT and vPvB assessment

### Product:

Assessment	: This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.
------------	--

## 12.6 Other adverse effects

### Product:

Endocrine disrupting potential	: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation
--------------------------------	--

# Betamethasone / Clotrimazole Ointment For- mulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
8.0	06.04.2024	610359-00020	Date of first issue: 08.04.2016

(EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

## SECTION 13: Disposal considerations

### 13.1 Waste treatment methods

- |                        |   |   |
|------------------------|---|---|
| Product                | : | Dispose of in accordance with local regulations. According to the European Waste Catalogue, Waste Codes are not product specific, but application specific. Waste codes should be assigned by the user, preferably in discussion with the waste disposal authorities. Do not dispose of waste into sewer. |
| Contaminated packaging | : | Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.  |

## SECTION 14: Transport information

### 14.1 UN number

- |      |   |         |
|------|---|---------|
| ADN  | : | UN 3077 |
| ADR  | : | UN 3077 |
| RID  | : | UN 3077 |
| IMDG | : | UN 3077 |
| IATA | : | UN 3077 |

### 14.2 UN proper shipping name

- |      |   |   |
|------|---|---|
| ADN  | : | ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S.<br>(betamethasone, clotrimazole) |
| ADR  | : | ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S.<br>(betamethasone, clotrimazole) |
| RID  | : | ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S.<br>(betamethasone, clotrimazole) |
| IMDG | : | ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S.<br>(betamethasone, clotrimazole) |
| IATA | : | Environmentally hazardous substance, solid, n.o.s.<br>(betamethasone, clotrimazole) |

### 14.3 Transport hazard class(es)

- |     | Class | Subsidiary risks |
|-----|-------|------------------|
| ADN | :     | 9                |
| ADR | :     | 9                |



# Betamethasone / Clotrimazole Ointment For- mulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
8.0	06.04.2024	610359-00020	Date of first issue: 08.04.2016

---

**RID** : 9

**IMDG** : 9

**IATA** : 9

## 14.4 Packing group

### ADN

Packing group : III  
 Classification Code : M7  
 Hazard Identification Number : 90  
 Labels : 9

### ADR

Packing group : III  
 Classification Code : M7  
 Hazard Identification Number : 90  
 Labels : 9  
 Tunnel restriction code : (-)

### RID

Packing group : III  
 Classification Code : M7  
 Hazard Identification Number : 90  
 Labels : 9

### IMDG

Packing group : III  
 Labels : 9  
 EmS Code : F-A, S-F

### IATA (Cargo)

Packing instruction (cargo aircraft) : 956  
 Packing instruction (LQ) : Y956  
 Packing group : III  
 Labels : Miscellaneous

### IATA (Passenger)

Packing instruction (passenger aircraft) : 956  
 Packing instruction (LQ) : Y956  
 Packing group : III  
 Labels : Miscellaneous

## 14.5 Environmental hazards

### ADN

Environmentally hazardous : yes

### ADR

Environmentally hazardous : yes

### RID

Environmentally hazardous : yes

### IMDG

Marine pollutant : yes

# SAFETY DATA SHEET



## Betamethasone / Clotrimazole Ointment Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
8.0	06.04.2024	610359-00020	Date of first issue: 08.04.2016

---

### IATA (Passenger)

Environmentally hazardous : yes

### IATA (Cargo)

Environmentally hazardous : yes

### 14.6 Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

### 14.7 Transport in bulk according to Annex II of Marpol and the IBC Code

Remarks : Not applicable for product as supplied.

---

## SECTION 15: Regulatory information

### 15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

#### The components of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

### 15.2 Chemical safety assessment

A Chemical Safety Assessment has not been carried out.

---

## SECTION 16: Other information

Other information : Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

### Full text of H-Statements

H302 : Harmful if swallowed.

H311 : Toxic in contact with skin.

H319 : Causes serious eye irritation.

H330 : Fatal if inhaled.

H360D : May damage the unborn child.

H361fd : Suspected of damaging fertility. Suspected of damaging the unborn child.

H372 : Causes damage to organs through prolonged or repeated exposure.

H373 : May cause damage to organs through prolonged or repeated exposure if swallowed.

H400 : Very toxic to aquatic life.

H410 : Very toxic to aquatic life with long lasting effects.

### Full text of other abbreviations

# Betamethasone / Clotrimazole Ointment Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
8.0	06.04.2024	610359-00020	Date of first issue: 08.04.2016

Acute Tox.	:	Acute toxicity
Aquatic Acute	:	Short-term (acute) aquatic hazard
Aquatic Chronic	:	Long-term (chronic) aquatic hazard
Eye Irrit.	:	Eye irritation
Repr.	:	Reproductive toxicity
STOT RE	:	Specific target organ toxicity - repeated exposure

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - Agreement concerning the International Carriage of Dangerous Goods by Road; AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA - European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of very high concern; TCSI - Taiwan Chemical Substance Inventory; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

## Further information

Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

### Classification of the mixture:

Repr. 1B	H360D
STOT RE 1	H372
Aquatic Chronic 1	H410

### Classification procedure:

Calculation method
Calculation method
Calculation method

# SAFETY DATA SHEET



## Betamethasone / Clotrimazole Ointment Formulation



Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
8.0	06.04.2024	610359-00020	Date of first issue: 08.04.2016

---

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

ZA / EN